Skip to main content

Cost-efficient European adaptations of global health economic models

Experience with model adaptations in Austria, Belgium, France, Germany, Italy, Norway, Netherlands, Spain, Sweden, the UK

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MTRC has released a White Paper "Challenges of HTA and Reimbursement Submissions for Medical Devices"

Securing reimbursement and obtaining HTA approval for medical technologies in Europe is a complex and variable process. Differences in submission requirements, evidence standards, and national regulations create significant challenges for MedTech companies, often delaying market entry. Successfully navigating these complexities requires country-specific knowledge and a strategic approach to evidence generation.

Our latest White Paper analyses these hurdles and offers practical solutions to streamline submissions and improve approval success rates. It highlights key challenges - such as inconsistencies in evidence expectations, language barriers, and misalignment with local clinical practices.

Read more and request a White Paper here.